Payment overview · 2025
General Payments
$459.78
18 reported records · 7 companies
Healthcare provider profile · identity verified
Jacob Sterling Gardner, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SARASOTA, FL · NPI 1639674047
Verified facts
What the public records show
CMS Open Payments records show Jacob Sterling Gardner, MD received $459.78 in general payments during 2025 across 18 reported records.
Novo Nordisk Inc accounted for 50.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus, Wegovy.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $229.70 | 50.0% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $76.16 | 16.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.84 | 11.9% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $36.20 | 7.9% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $29.86 | 6.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.10 | 4.2% | 1 | 2025 |
| Nalu Medical, Inc. | Unresolved — no canonical attribution shown | $13.92 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $459.78 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $199.25 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.09 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $46.27 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $39.81 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.81 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $36.20 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.45 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.89 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $29.86 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| Nalu Neurostimulation System Normalized: nalu neurostimulation system |
Device | Nalu Medical, Inc. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 76 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 61 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 672 | 192 |
| Levothyroxine Sodium | Levothyroxine Sodium | 557 | 158 |
| Amlodipine Besylate | Amlodipine Besylate | 535 | 164 |
| Losartan Potassium | Losartan Potassium | 493 | 139 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 437 | 142 |
| Omeprazole | Omeprazole | 408 | 123 |
| Lisinopril | Lisinopril | 345 | 101 |
| Tamsulosin Hcl | Tamsulosin Hcl | 287 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 271 | 79 |
| Simvastatin | Simvastatin | 250 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 249 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 244 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 228 | 78 |
| Pravastatin Sodium | Pravastatin Sodium | 210 | 64 |
| Methylprednisolone | Methylprednisolone | 207 | 177 |
| Metformin Hcl | Metformin Hcl | 205 | 61 |
| Gabapentin | Gabapentin | 192 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 188 | 95 |
| Allopurinol | Allopurinol | 175 | 55 |
| Ezetimibe | Ezetimibe | 161 | 44 |
| Alprazolam | Alprazolam | 157 | 64 |
| Furosemide | Furosemide | 151 | 59 |
| Celecoxib | Celecoxib | 141 | 52 |
| Metformin Hcl Er | Metformin Hcl | 136 | 46 |
| Atenolol | Atenolol | 134 | 41 |
| Lorazepam | Lorazepam | 131 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 46 |
| Trazodone Hcl | Trazodone Hcl | 124 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 54 |
| Eliquis | Apixaban | 118 | 28 |
| Finasteride | Finasteride | 118 | 38 |
| Potassium Chloride | Potassium Chloride | 113 | 45 |
| Sertraline Hcl | Sertraline Hcl | 110 | 39 |
| Meloxicam | Meloxicam | 108 | 48 |
| Montelukast Sodium | Montelukast Sodium | 104 | 31 |
| Ozempic | Semaglutide | 102 | 21 |
| Synthroid | Levothyroxine Sodium | 102 | 27 |
| Azithromycin | Azithromycin | 101 | 94 |
| Famotidine | Famotidine | 98 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 23 |
| Tramadol Hcl | Tramadol Hcl | 91 | 32 |
| Prednisone | Prednisone | 89 | 47 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 87 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 37 |
| Jardiance | Empagliflozin | 76 | 16 |
| Valsartan | Valsartan | 76 | 21 |
| Glipizide Er | Glipizide | 73 | 29 |
| Carvedilol | Carvedilol | 71 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 62 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 21 |
| Clonazepam | Clonazepam | 61 | 22 |
| Mounjaro | Tirzepatide | 61 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 17 |
| Benazepril Hcl | Benazepril Hcl | 58 | 17 |
| Bupropion Xl | Bupropion Hcl | 58 | 22 |
| Lovastatin | Lovastatin | 52 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 15 |
| Alendronate Sodium | Alendronate Sodium | 49 | 15 |
| Ramipril | Ramipril | 47 | 11 |
| Xarelto | Rivaroxaban | 47 | 15 |
| Amoxicillin | Amoxicillin | 44 | 35 |
| Fenofibrate | Fenofibrate | 44 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 29 |
| Buspirone Hcl | Buspirone Hcl | 41 | 11 |
| Estradiol | Estradiol | 40 | 15 |
| Temazepam | Temazepam | 40 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 39 | 39 |
| Primidone | Primidone | 38 | 13 |
| Valacyclovir | Valacyclovir Hcl | 38 | 19 |
| Propranolol Hcl | Propranolol Hcl | 37 | 13 |
| Ketoconazole | Ketoconazole | 36 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 35 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 26 |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 26 |
| Spironolactone | Spironolactone | 33 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 20 |
| Mupirocin | Mupirocin | 32 | 26 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 24 |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Wegovy | Semaglutide | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 19 |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Nystatin | Nystatin | 20 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Lactulose | Lactulose | 13 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $459.78 · 18 records | Novo Nordisk Inc | APRETUDE, Cologuard Collection Kit, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, Nalu Neurostimulation System, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, Veozah, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error